Compare Commvault Systems Inc (CVLT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs TransMedics Group Inc — how do they compare? Commvault Systems Inc trades at $141.97 (market cap $5.78B), while TransMedics Group Inc trades at $87 (market cap $3.10B). The key difference: Commvault Systems Inc is the larger of the two by market cap, and Commvault Systems Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| CVLT | TMDX | |
|---|---|---|
Market Cap | $5.78B | $3.10B |
Sector | Technology | Technology |
52-Week High | $195.41 | $150.42 |
52-Week Low | $75.18 | $61.99 |
Enterprise Value | $5.76B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $141.74, up 1.66% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.42 per share, beating estimates, and has a consensus analyst price target of $172.40. Revenue growth is robust, with 2026 projections at $1.2 billion, though net income margin is expected to compress. Recent news includes a shareholder investigation and positive developments in threat scan integration.
The outlook is positive given earnings beats and subscription growth, but high valuation ratios (P/E of 89.35) and margin pressure pose risks. Investor sentiment is buoyed by analyst buy ratings (54.55%), though legal scrutiny and competitive threats require monitoring for sustained upside.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
